Point72 Asia Singapore Pte. Ltd. Takes $84,000 Position in Mural Oncology plc (NASDAQ:MURA)

Point72 Asia Singapore Pte. Ltd. bought a new position in Mural Oncology plc (NASDAQ:MURA) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 26,642 shares of the company’s stock, valued at approximately $84,000. Point72 Asia Singapore Pte. Ltd. owned about 0.16% of Mural Oncology at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. BBR Partners LLC bought a new position in shares of Mural Oncology in the 2nd quarter worth approximately $31,000. Rhumbline Advisers bought a new position in Mural Oncology in the second quarter worth approximately $34,000. Canada Pension Plan Investment Board purchased a new position in shares of Mural Oncology during the 2nd quarter worth $70,000. Dimensional Fund Advisors LP purchased a new position in shares of Mural Oncology during the 2nd quarter worth $71,000. Finally, Cubist Systematic Strategies LLC bought a new stake in shares of Mural Oncology during the 2nd quarter valued at $98,000. Hedge funds and other institutional investors own 80.21% of the company’s stock.

Insider Transactions at Mural Oncology

In other news, CEO Caroline Loew sold 12,531 shares of the firm’s stock in a transaction dated Monday, July 8th. The stock was sold at an average price of $2.91, for a total transaction of $36,465.21. Following the completion of the transaction, the chief executive officer now owns 240,391 shares in the company, valued at $699,537.81. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 0.06% of the company’s stock.

Mural Oncology Stock Up 5.0 %

Shares of Mural Oncology stock opened at $3.36 on Friday. Mural Oncology plc has a fifty-two week low of $2.88 and a fifty-two week high of $17.00. The company has a fifty day moving average of $3.25 and a 200 day moving average of $3.53.

Mural Oncology (NASDAQ:MURA) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($1.86) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.90) by $0.04. On average, analysts anticipate that Mural Oncology plc will post -7.54 earnings per share for the current year.

Analysts Set New Price Targets

MURA has been the topic of several analyst reports. Raymond James began coverage on Mural Oncology in a research report on Friday. They set a “strong-buy” rating and a $18.00 target price on the stock. Rodman & Renshaw started coverage on Mural Oncology in a research note on Friday, June 28th. They set a “buy” rating and a $15.00 price objective for the company.

Mural Oncology Profile

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.